These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2163 related items for PubMed ID: 26962872

  • 21. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S.
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [Abstract] [Full Text] [Related]

  • 22. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T, Li Z, Xu L, Zhang Y, Chen H, Gao Y.
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [Abstract] [Full Text] [Related]

  • 23. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M, Stordal B.
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [Abstract] [Full Text] [Related]

  • 24. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S, Zhang XC, Cheng H, Zhu JQ, Chen ZH, Zhang YF, Xie Z, Wu YL.
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [Abstract] [Full Text] [Related]

  • 25. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA.
    Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
    [Abstract] [Full Text] [Related]

  • 26. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
    Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, Liu M, Pang X.
    Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
    [Abstract] [Full Text] [Related]

  • 27. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
    Fu S, Liu C, Huang Q, Fan S, Tang H, Fu X, Ai B, Liao Y, Chu Q.
    Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
    [Abstract] [Full Text] [Related]

  • 28. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL.
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
    [Abstract] [Full Text] [Related]

  • 29. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [Abstract] [Full Text] [Related]

  • 30. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
    Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y, Yano S.
    Cancer Res; 2013 Apr 15; 73(8):2428-34. PubMed ID: 23382048
    [Abstract] [Full Text] [Related]

  • 31. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
    Formisano L, D'Amato V, Servetto A, Brillante S, Raimondo L, Di Mauro C, Marciano R, Orsini RC, Cosconati S, Randazzo A, Parsons SJ, Montuori N, Veneziani BM, De Placido S, Rosa R, Bianco R.
    Oncotarget; 2015 Sep 22; 6(28):26090-103. PubMed ID: 26325669
    [Abstract] [Full Text] [Related]

  • 32. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D, Santini S, Cardinali B, Papoff G, Lalli C, Samperna S, Fustaino V, Giannini G, Ruberti G.
    PLoS One; 2015 Sep 22; 10(11):e0143333. PubMed ID: 26580964
    [Abstract] [Full Text] [Related]

  • 33. Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.
    Dal Bello MG, Alama A, Barletta G, Coco S, Truini A, Vanni I, Boccardo S, Genova C, Rijavec E, Biello F, Bottoni G, Sambuceti G, Grossi F.
    Int J Cancer; 2015 Dec 15; 137(12):2947-58. PubMed ID: 26089022
    [Abstract] [Full Text] [Related]

  • 34. Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation.
    Kim N, Cho A, Watanabe H, Choi YL, Aziz M, Kassner M, Joung JG, Park AK, Francis JM, Bae JS, Ahn SM, Kim KM, Park JO, Park WY, Ahn MJ, Park K, Koo J, Yin HH, Cho J.
    Oncotarget; 2016 Mar 22; 7(12):13797-809. PubMed ID: 26883194
    [Abstract] [Full Text] [Related]

  • 35. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K, Hata A, Takeshita J, Okuda C, Kaji R, Masago K, Fujita S, Katakami N.
    Cancer Chemother Pharmacol; 2015 Oct 22; 76(4):835-41. PubMed ID: 26349474
    [Abstract] [Full Text] [Related]

  • 36. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W, Chen Y, Zhu KY, Deng H, Wu T, Wang J.
    Biol Pharm Bull; 2017 Aug 01; 40(8):1306-1313. PubMed ID: 28515374
    [Abstract] [Full Text] [Related]

  • 37. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM, Wozniak A.
    Clin Lung Cancer; 2013 Jul 01; 14(4):322-32. PubMed ID: 23332287
    [Abstract] [Full Text] [Related]

  • 38. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q, Ling YH, Lia M, Zou YY, Kroog G, Iwata KK, Perez-Soler R.
    Clin Cancer Res; 2005 Feb 15; 11(4):1572-8. PubMed ID: 15746062
    [Abstract] [Full Text] [Related]

  • 39. Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3.
    Tang J, Guo F, Du Y, Liu X, Qin Q, Liu X, Yin T, Jiang L, Wang Y.
    Int J Oncol; 2015 May 15; 46(5):2083-95. PubMed ID: 25695284
    [Abstract] [Full Text] [Related]

  • 40. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
    Ma P, Zhang M, Nie F, Huang Z, He J, Li W, Han L.
    Biomed Pharmacother; 2017 Mar 15; 87():20-26. PubMed ID: 28040594
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 109.